Relief Therapeutics Indicates Prolonged Release Of Amino Acids Using Its Physiomimictm Technology May Benefit For The Treatment Of Pku
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company focused on providing therapeutic relief to patients with serious diseases with high unmet needs, today announced that its wholly-owned subsidiary, APR Applied Pharma Research SA (“APR”), published data in the peer-reviewed International Journal of Molecular Sciences indicating that prolonged release of amino acids formulated with APR’s PhysiomimicTM Technology may have dietary management benefits.
“The paper’s conclusions confirm the advantages of prolonged AA absorption using our patented PhysiomimicTM Technology, which has already been demonstrated in humans. The prolonged release of AAs made possible through our PhysiomimicTM Technology and used in the currently commercialized PKU GOLIKE family of products in Europe, we believe, leads to absorption of AAs more closely resembling the natural protein in healthy humans, providing a distinct advantage for the treatment of patients with PKU. We are relentlessly working to bring PKU GOLIKE as a treatment to PKU patients in the U.S. within 2022 while we are in the process of generating further clinical evidence that will support PKU GOLIKE as a prescription product,”Paolo Galfetti, Chief Executive Officer of APR and President of Relief Europe.
The study, titled “In Vivo Metabolic Responses to Different Formulations of Amino Acid Mixtures for the Treatment of Phenylketonuria (PKU),” looked at the impact of a prolonged release of AA formulation on nitrogen balance in both acute and long-term experimental studies to see how it compared to the natural slow-release reference protein casein or free AA controls. The paper’s authors, include Prof. Dr. Jlio César Rocha, Assistant Professor at NOVA Medical School, Faculty of Medical Sciences, NOVA University of Lisbon Reference Centre for Inherited Metabolic Diseases, Centro Hospitalar Universitário de Lisboa Central, and CINTESIS Portugal, came to the conclusion that the prolonged release of an amino acid mix found in PKU GOLIKE may have beneficial effects on both AA oxidation and catabolism, with a direct impact on muscle mass and The findings of this trial paved the way for more human studies to demonstrate the benefits of the PhysiomimicTM Technology AA formulation in the dietary therapy of PKU.